"Healey & AMG Center announces top line results in ALS platform trial with CMN-Au8," published by the Sean M. Healey & AMG Center for ALS
A secondary endpoint analysis of survival demonstrated a significant reduction in risk of death or permanently assisted ventilation when adjusting for baseline risk imbalances in the CNM-Au8 regimen for the 30 mg dose at 24 weeks